|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kleeff J, Reiser C, Hinz U, Bachmann J,
Debus J, Jaeger D, Friess H and Büchler MW: Surgery for recurrent
pancreatic ductal adenocarcinoma. Ann Surg. 245:566–572. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang C, Liu B, Xu X, Zhuang B, Li H, Yin
J, Cong M, Xu W and Lu A: Toward targeted therapy in
chemotherapy-resistant pancreatic cancer with a smart triptolide
nanomedicine. Oncotarget. 7:8360–8372. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Murakami T, Hiroshima Y, Matsuyama R,
Homma Y, Hoffman RM and Endo I: Role of the tumor microenvironment
in pancreatic cancer. Ann Gastroenterol Surg. 3:130–137. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ferrara B, Pignatelli C, Cossutta M, Citro
A, Courty J and Piemonti L: The extracellular matrix in pancreatic
cancer: Description of a complex network and promising therapeutic
options. Cancers (Basel). 13:44422021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cukierman E and Bassi DE:
Physico-mechanical aspects of extracellular matrix influences on
tumorigenic behaviors. Semin Cancer Biol. 20:139–145. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pickup MW, Mouw JK and Weaver VM: The
extracellular matrix modulates the hallmarks of cancer. EMBO Rep.
15:1243–1253. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Laklai H, Miroshnikova YA, Pickup MW,
Collisson EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer
DD, Mouw JK, et al: Genotype tunes pancreatic ductal adenocarcinoma
tissue tension to induce matricellular fibrosis and tumor
progression. Nat Med. 22:497–505. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Olive KP, Jacobetz MA, Davidson CJ,
Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA,
Caldwell ME, Allard D, et al: Inhibition of Hedgehog signaling
enhances delivery of chemotherapy in a mouse model of pancreatic
cancer. Science. 324:1457–1461. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jacobetz MA, Chan DS, Neesse A, Bapiro TE,
Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, et
al: Hyaluronan impairs vascular function and drug delivery in a
mouse model of pancreatic cancer. Gut. 62:112–120. 2013. View Article : Google Scholar
|
|
15
|
Weniger M, Honselmann KC and Liss AS: The
extracellular matrix and pancreatic cancer: A complex relationship.
Cancers (Basel). 10:3162018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ueno H, Kiyosawa K and Kaniwa N:
Pharmacogenomics of gemcitabine: Can genetic studies lead to
tailor-made therapy? Br J Cancer. 97:145–151. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Q, Liu X, Zhou J, Huang Y, Zhang S,
Shen J, Loera S, Yuan X, Chen W, Jin M, et al: Ribonucleotide
reductase large subunit M1 predicts poor survival due to modulation
of proliferative and invasive ability of gastric cancer. PLoS One.
8:e701912013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie H, Jiang W, Jiang J, Wang Y, Kim R and
Liu X and Liu X: Predictive and prognostic roles of ribonucleotide
reductase M1 in resectable pancreatic adenocarcinoma. Cancer.
119:173–181. 2013. View Article : Google Scholar
|
|
19
|
Kato T, Ono H, Fujii M, Akahoshi K, Ogura
T, Ogawa K, Ban D, Kudo A, Tanaka S and Tanabe M: Cytoplasmic RRM1
activation as an acute response to gemcitabine treatment is
involved in drug resistance of pancreatic cancer cells. PLoS One.
16:e02529172021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Han QL, Zhou YH, Lyu Y, Yan H and Dai GH:
Effect of ribonucleotide reductase M1 expression on overall
survival in patients with pancreatic cancer receiving gemcitabine
chemotherapy: A literature-based meta-analysis. J Clin Pharm Ther.
43:163–169. 2018. View Article : Google Scholar
|
|
21
|
Nakano Y, Tanno S, Koizumi K, Nishikawa T,
Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T and Kohgo
Y: Gemcitabine chemoresistance and molecular markers associated
with gemcitabine transport and metabolism in human pancreatic
cancer cells. Br J Cancer. 96:457–463. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ono H, Basson MD and Ito H: PTK6
potentiates gemcitabine-induced apoptosis by prolonging S-phase and
enhancing DNA damage in pancreatic cancer. Mol Cancer Res.
13:1174–1184. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ono H, Basson MD and Ito H: PTK6 promotes
cancer migration and invasion in pancreatic cancer cells dependent
on ERK signaling. PLoS One. 9:e960602014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
25
|
Ono H, Basson MD and Ito H: P300
inhibition enhances gemcitabine-induced apoptosis of pancreatic
cancer. Oncotarget. 7:51301–51310. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Watanabe S, Shimada S, Akiyama Y, Ishikawa
Y, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, et al: Loss
of KDM6A characterizes a poor prognostic subtype of human
pancreatic cancer and potentiates HDAC inhibitor lethality. Int J
Cancer. 145:192–205. 2019. View Article : Google Scholar
|
|
27
|
Young MD, Wakefield MJ, Smyth GK and
Oshlack A: Gene ontology analysis for RNA-seq: Accounting for
selection bias. Genome Biol. 11:R142010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou B, Guo W, Sun C, Zhang B and Zheng F:
Linc00462 promotes pancreatic cancer invasiveness through the
miR-665/TGFBR1-TGFBR2/SMAD2/3 pathway. Cell Death Dis. 9:7062018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang G, Guan W, Cao Z, Guo W, Xiong G,
Zhao F, Feng M, Qiu J, Liu Y, Zhang MQ, et al: Integrative genomic
analysis of gemcitabine resistance in pancreatic cancer by
patient-derived xenograft models. Clin Cancer Res. 27:3383–3396.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Arumugam T, Ramachandran V, Fournier KF,
Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey
DJ and Choi W: Epithelial to mesenchymal transition contributes to
drug resistance in pancreatic cancer. Cancer Res. 69:5820–5828.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Z, Li Y, Kong D, Banerjee S, Ahmad A,
Azmi AS, Ali S, Abbruzzese JL, Gallick GE and Sarkar FH:
Acquisition of epithelial-mesenchymal transition phenotype of
gemcitabine-resistant pancreatic cancer cells is linked with
activation of the notch signaling pathway. Cancer Res.
69:2400–2407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang R, Cheng L, Xia J and Wang Z, Wu Q
and Wang Z: Gemcitabine resistance is associated with
epithelial-mesenchymal transition and induction of HIF-1α in
pancreatic cancer cells. Curr Cancer Drug Targets. 14:407–417.
2014. View Article : Google Scholar
|
|
33
|
Duxbury MS, Ito H, Zinner MJ, Ashley SW
and Whang EE: Inhibition of SRC tyrosine kinase impairs inherent
and acquired gemcitabine resistance in human pancreatic
adenocarcinoma cells. Clin Cancer Res. 10:2307–2318. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Meidhof S, Brabletz S, Lehmann W, Preca
BT, Mock K, Ruh M, Schüler J, Berthold M, Weber A, Burk U, et al:
ZEB1-associated drug resistance in cancer cells is reversed by the
class I HDAC inhibitor mocetinostat. EMBO Mol Med. 7:831–847. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jiang X, Li Y, Zhang N, Gao Y, Han L, Li
S, Li J, Liu X, Gong Y and Xie C: RRM2 silencing suppresses
malignant phenotype and enhances radiosensitivity via activating
cGAS/STING signaling pathway in lung adenocarcinoma. Cell Biosci.
11:742021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wen D, Huang Z, Li Z, Tang X, Wen X, Liu J
and Li M: LINC02535 co-functions with PCBP2 to regulate DNA damage
repair in cervical cancer by stabilizing RRM1 mRNA. J Cell Physiol.
235:7592–7603. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jiang C, Xu R, Li XX, Wang YY, Liang WQ,
Zeng JD, Zhang SS, Xu XY, Yang Y, Zhang MY, et al: p53R2
overexpression in cervical cancer promotes AKT signaling and EMT,
and is correlated with tumor progression, metastasis and poor
prognosis. Cell Cycle. 16:1673–1682. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nakajima S, Doi R, Toyoda E, Tsuji S, Wada
M, Koizumi M, Tulachan SS, Ito D, Kami K, Mori T, et al: N-cadherin
expression and epithelial-mesenchymal transition in pancreatic
carcinoma. Clin Cancer Res. 10:4125–4133. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang H, Zhou H, Ni H and Shen X:
COL11A1-driven epithelial-mesenchymal transition and stemness of
pancreatic cancer cells induce cell migration and invasion by
modulating the AKT/GSK-3β/snail pathway. Biomolecules. 12:3912022.
View Article : Google Scholar
|
|
40
|
Paron I, Berchtold S, Vörös J, Shamarla M,
Erkan M, Höfler H and Esposito I: Tenascin-C enhances pancreatic
cancer cell growth and motility and affects cell adhesion through
activation of the integrin pathway. PLoS One. 6:e216842011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Juuti A, Nordling S, Louhimo J, Lundin J
and Haglund C: Tenascin C expression is upregulated in pancreatic
cancer and correlates with differentiation. J Clin Pathol.
57:1151–1155. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang H, Ren R, Yang Z, Cai J, Du S and
Shen X: The COL11A1/Akt/CREB signaling axis enables
mitochondrial-mediated apoptotic evasion to promote chemoresistance
in pancreatic cancer cells through modulating BAX/BCL-2 function. J
Cancer. 12:1406–1420. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shi M, He X, Wei W, Wang J, Zhang T and
Shen X: Tenascin-C induces resistance to apoptosis in pancreatic
cancer cell through activation of ERK/NF-κB pathway. Apoptosis.
20:843–857. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Park H, Lee Y, Lee H, Kim JW, Hwang JH,
Kim J, Yoon YS, Han HS and Kim H: The prognostic significance of
cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.
Tumour Biol. 39:10104283177184032017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Leppänen J, Lindholm V, Isohookana J,
Haapasaari KM, Karihtala P, Lehenkari PP, Saarnio J, Kauppila JH,
Karttunen TJ, Helminen O and Huhta H: Tenascin C, fibronectin, and
tumor-stroma ratio in pancreatic ductal adenocarcinoma. Pancreas.
48:43–48. 2019. View Article : Google Scholar
|
